The North America Protein Crystallization & Crystallography Market is witnessing significant growth driven by advancements in structural biology, increased R&D investments by pharmaceutical companies, and the emergence of cutting-edge crystallization technologies. The market was valued at USD 1,210 Million in 2025 and is projected to reach USD 2,945 Million by 2035, growing at a CAGR of 8.7% from 2024 to 2035.
The economic impact of tariffs on "North America Protein Crystallization & Crystallography Market".
Market Growth Drivers
Rising Investments in Drug Discovery and Structural Biology: The surge in drug discovery activities, particularly biologics and precision medicine, is fueling demand for efficient protein crystallization techniques. Major pharma players like Pfizer have increased funding for structural biology research to accelerate drug development, leveraging advanced crystallography solutions for precise protein structure determination.
Technological Advancements in Crystallization Instruments: Companies such as Rigaku Corporation are introducing automated and high-throughput crystallization instruments, reducing manual intervention and increasing throughput. These innovations streamline workflows in academic and pharmaceutical research, supporting rapid identification of protein structures critical for therapeutics development.
Market Trends
Integration of Artificial Intelligence (AI) for Structure Prediction: The adoption of AI tools, such as DeepMind’s AlphaFold, has revolutionized the field by predicting protein structures with remarkable accuracy. This trend is being adopted by North American labs and companies, with Thermo Fisher Scientific integrating AI algorithms into their crystallography platforms to enhance structural prediction capabilities.
Expansion of Cryo-Electron Microscopy (Cryo-EM): While protein crystallography remains a core technique, the rising utilization of Cryo-EM is influencing crystallography workflows. Companies like Bruker are enhancing their product offerings to combine crystallography and Cryo-EM solutions, pushing the boundaries for resolution and analysis in structural biology.
Market Opportunity
Development of Novel Therapies Targeting Infectious Diseases: The COVID-19 pandemic has spotlighted the need for rapid protein structure analysis to develop effective antivirals. Companies like GenScript are seizing opportunities to collaborate with research institutes for the development of diagnostic and therapeutic solutions using advanced crystallization techniques.
Penetration in Academic Research: Universities and research centers are expanding their protein crystallization capabilities, presenting opportunities for equipment suppliers like Mettler-Toledo to provide advanced crystallography systems and consumables, thereby broadening their market within the academic segment.
The chart shows a steady and substantial growth trajectory for the North America Protein Crystallization & Crystallography Market from 2020 to 2035. Starting at USD 740 Million in 2020, the market sees a consistent rise, fueled by strong research funding, pharma collaborations, and technological advancements. By 2025, the market crosses the USD 1,210 Million mark and continues its substantial climb, projected to reach USD 2,945 Million by 2035. The double-digit CAGR underscores a long-term robust demand, with pharmaceutical and academic research driving market expansion, indicating a lucrative opportunity for innovative vendors and solution providers.
Market by Regions Share (%), 2025
The 2025 regional market share pie chart highlights the dominance of the United States, accounting for 77% of the North American Protein Crystallization & Crystallography Market, driven by a strong biopharmaceutical sector and expansive R&D base. Canada captures 13%, reflecting growing investments in academic research and healthcare innovation, while Mexico contributes 7%, fueled by increasing collaborations in biotechnology. Other regions, including emerging markets, make up the remaining 3%. The chart illustrates clear leadership by the United States while underlining the expanding opportunities across Canada and Mexico.
Recent Developments
In February 2024, Thermo Fisher Scientific announced the launch of its new automated protein crystallization platform, integrating AI-driven protocols to facilitate high-throughput screening. The platform allows simultaneous experiment tracking and advanced imaging, reducing analysis time by 30%. This launch aims to cater to pharmaceutical clients accelerating drug pipeline research in North America.
In March 2024, Rigaku Corporation signed a strategic partnership with the University of Toronto to establish an advanced crystallography research center. This facility will focus on novel crystallization methods and industry-academia collaborative projects, targeting faster structure-based drug design and boosting translational research activities in the region.
In May 2024, Bruker unveiled its upgraded D8 QUEST X-ray diffractometer for protein crystallography applications, improving resolution and data accuracy. The company highlighted ongoing installations in key academic labs and biotech industry partnerships, underscoring North America's growing demand for precision structural biology instruments.
Press Releases